pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
639
stories
8d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
8d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
stat
9d
Samsung hearing aid features for its ear buds garner FDA clearance
fiercebiotech
9d
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
9d
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
fiercebiotech
9d
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
biospace
9d
STAT+: Skylark Bio kicks off new gene therapy trial for deafness
stat
9d
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
biospace
10d
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
stat
10d
Recon: FDA rejects ITM radiopharma therapy; WHO defends immunization schedules
raps
10d
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
biopharma dive
10d
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
10d
FDA to require notice of additives in food supply for the first time
stat
10d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
10d
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
10d
Tenax shares nosedive as heart failure drug fails in Phase 3
biospace
10d
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
10d
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
stat
10d
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
biospace
10d
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
fiercebiotech
10d
Denali climbs past Avlayah expectations with $3.6M in revenue
biospace
11d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
11d
STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed
stat
11d
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
11d
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
11d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
11d
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
11d
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
← prev
page 4 of 22
next →
